Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Ryan Orgel Daniel Wojdyla David Huberman Jonathan L Halperin Günter Breithardt Daniel E Singer Keith A A Fox Graeme J Hankey Kenneth W Mahaffey W Schuyler Jones Manesh R Patel

Circ Cardiovasc Qual Outcomes

From the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.O., D.W., W.S.J., M.R.P.); Department of Statistics, North Carolina State University, Raleigh (D.H.); Mount Sinai Medical Center, New York, NY (J.L.H.); Department of Cardiovascular Medicine, Hospital of the University of Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); University of Edinburgh and Royal Infirmary of Edinburgh, Scotland, United Kingdom (K.A.A.F.); School of Medicine and Pharmacology, University of Western Australia, Crawley (G.J.H.); and Stanford University School of Medicine, CA (K.W.M.).

Published: May 2017

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485838	PMC
http://dx.doi.org/10.1161/CIRCOUTCOMES.116.003520	DOI Listing

Publication Analysis

Top Keywords

atrial fibrillation

noncentral nervous

nervous system

system systemic

systemic embolism

embolism patients

patients atrial

fibrillation rocket

rocket rivaroxaban

rivaroxaban daily

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!